Print 2

Obstructive Airway Pathologies: Asthma & Paradoxical Vocal Fold Movement

  • Asthma Pathophysiology & Presentation:

    • Chronic lower airway disease characterized by bronchial inflammation, bronchoconstriction, and excessive mucus viscosity.

    • Impairs expiration, reducing respiratory driving pressure for speech and causing wheezing, coughing, and chest tightness.

    • Secondary clinical impacts include dysphagia from altered tongue movements and delayed swallow reflex initiation.

    • Medical management includes inhaled corticosteroids, bronchodilators, nebulizers, and leukotriene modifiers.

  • Paradoxical Vocal Fold Movement (PVFM):

    • Episodic upper airway obstruction characterized by abnormal adduction of true vocal folds during inspiration.

    • Triggers dyspnea, inhalatory stridor, panic, and an acute inability to phonate or safely coordinate swallowing.

    • Etiologies categorized as organic, environmental, or psychosocial.

  • Speech-Language Pathology Interventions:

    • Asthma: Vocal hygiene education, rinsing after inhaler use, cough-suppression techniques, and swallow-respiration pacing.

    • PVFM: Direct techniques including relaxed-throat breathing, pursed-lip breathing, and diaphragmatic breathing; indirect methods include irritant avoidance, desensitization (such as Heliox mask), laryngeal massage, and supportive counseling.

Chronic Cardiopulmonary Conditions: COPD & Congestive Heart Failure

  • Chronic Obstructive Pulmonary Disease (COPD):

    • Progressive, irreversible condition encompassing chronic bronchitis and emphysema leading to airway obstruction and alveolar destruction.

    • Produces breathy voice quality, reduced vocal loudness, short phrase duration, and high risk of aspiration due to discoordination between breathing and swallowing.

    • Interventions include smoking cessation, bronchodilators, anti-inflammatory inhalers, oxygen therapy, and pulmonary rehabilitation.

  • Congestive Heart Failure (CHF):

    • Progressive cardiac failure where weakened or stiffened ventricles fail to pump adequate systemic blood flow, leading to organ congestion and fluid backup.

    • Manifests with exertional dyspnea, conversational breathlessness, vocal fatigue, and secondary dysphagia from general weakness or intubation.

    • Medical management consists of sodium restriction (<2000 mg< 2000\,mg), diuretics, ACE inhibitors, ARBs, ARNIs, and beta-blockers.

  • Clinical Swallowing & Speech Management:

    • Assessments include Clinical Swallowing Evaluations, Videofluoroscopic Swallowing Studies (VFSS), and Fiberoptic Endoscopic Evaluation of Swallowing (FEES).

    • Therapeutic interventions center on compensatory strategy training (77%77\% reporting rate among treating SLPs), breathing-swallowing coordination, diet/liquid modification, and phrase-length management.

Progressive Motor Neuron & Neurodegenerative Disorders: ALS, FA, & Parkinson's Disease

  • Amyotrophic Lateral Sclerosis (ALS):

    • Progressive degeneration of upper and lower motor neurons; approximately 10%10\% of cases possess a genetic basis.

    • Symptoms begin with muscle twitching, cramping, and distal extremity weakness, progressing to mixed dysarthria, profound dysphagia, and respiratory failure.

    • Medical therapies include Riluzole, Edaravone, and Qalsody (tofersen) for SOD1 mutations; ventilatory support includes noninvasive ventilation and tracheostomy.

    • SLP focus: Early alternative and augmentative communication (AAC) implementation, energy preservation, and swallow safety.

  • Friedreich's Ataxia (FA):

    • Inherited autosomal recessive disease caused by trinucleotide GAA repeat expansions (>100> 100 repeats) in the FXN gene on chromosome 9, affecting 1 in 40,0001\text{ in }40{,}000 individuals globally.

    • Onset occurs between ages 5 and 15, damaging the cerebellum, spinal cord, and peripheral nerves; individuals are frequently wheelchair-bound after 10 to 20 years.

    • Characterized by sensory and motor ataxia, scoliosis, dysarthria, and dysphagia. Medication includes Skyclarys; SLP interventions use Expiratory Muscle Strength Training (EMST) and Lee Silverman Voice Treatment (LSVT).

  • Parkinson's Disease (PD):

    • Degeneration of dopaminergic neurons within the substantia nigra, depleting dopamine in the basal ganglia.

    • Cardinal motor signs: Bradykinesia, rigidity, resting tremor, and masked facial expressions (hypomimia).

    • Speech and respiratory deficits: Hypokinetic dysarthria in approximately 90%90\% of individuals, dysphagia in 82%82\%, reduced vital capacity (VCVC), chest wall excursion restriction, and irregular respiratory cycles.

    • Interventions: Carbidopa-Levodopa pharmacotherapy, Deep Brain Stimulation (DBS), LSVT LOUD, EMST/IMST, air-stacking maneuvers, and sensorimotor airway protection training.

Demyelinating & Spinal Disorders: Multiple Sclerosis & Spinal Cord Injury

  • Multiple Sclerosis (MS):

    • Autoimmune demyelination of the central nervous system marked by sclerotic plaques across oligodendroglia; subtypes include benign, relapsing-remitting, remitting-progressive, and progressing.

    • Speech/Voice/Cognitive signs: Mixed spastic-ataxic dysarthria, scanning speech, vocal cord paresis causing breathy/harsh dysphonia, cognitive-linguistic processing delays, word-finding deficits (40% to 60%40\% \text{ to } 60\%), and dysphagia.

    • SLP treatments: LSVT LOUD protocols for hypophonia, compensatory swallowing strategies, assisted cough maneuvers, and diadochokinetic (DDK) diagnostic rate tracking.

  • Spinal Cord Injury (SCI):

    • Neurological disruption classified as complete (loss of all motor/sensory function below injury) or incomplete.

    • High cervical lesions (C1–C5C1\text{--}C5) impact the phrenic motor nucleus (C3–C5C3\text{--}C5 innervating the diaphragm), producing partial or total diaphragmatic paralysis.

    • Thoracic lesions compromise intercostal and abdominal muscle activation, diminishing peak cough flow, vital capacity, and voice projection.

    • Dysphagia occurs in approximately 31%31\% of cervical SCI patients. Management involves mechanical ventilation, diaphragm pacing, noninvasive ventilatory assistance, and speaking valve accommodation.

Anatomical diagram of phrenic nerve origin from C3-C5 innervating the diaphragm

Musculoskeletal & Structural Spinal Disorders

  • Structural Deformities:

    • Scoliosis: Lateral spinal curvature disrupting vertical alignment, compressing thoracic cavities and impeding lung inflation.

    • Lordosis: Exaggerated anterior lumbar curvature ("swayback") limiting ribcage excursion; cervical lordosis directly impairs anterior-superior laryngeal elevation during deglutition.

    • Kyphosis: Exaggerated posterior thoracic curvature (e.g., Dowager's hump from osteoporosis) causing mechanical inefficiency of suprahyoid muscles during swallowing.

    • Myotonic Muscular Dystrophy: Membrane breakdown and intracellular calcium overload driving progressive muscle atrophy, leading to flaccid dysarthria and ventilatory insufficiency.

Spinal curvatures comparing normal spine, scoliosis, kyphosis, and lordosis
  • Diagnostic Instruments & Therapies:

    • Assessments: Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V), Voice Handicap Index (VHI), Goldman-Fristoe Test of Articulation (GFTA-3), Khan-Lewis Phonological Analysis (KLPA-3), FEES, and Modified Barium Swallow Studies (MBSS).

    • Interventions: Laryngeal Manual Therapy (LMT) to reduce hyperfunctional muscle tension, posture/head positioning modifications, pacing, and clear speech articulation drills.

Airway Management: Tracheostomy & Mechanical Ventilation

  • Physiological Impact:

    • Placement of a tracheostomy tube bypasses the upper airway, eliminating natural warming, humidification, and filtration of air.

    • Diversion of expired air through the tracheal stoma disrupts airflow across true vocal cords, causing aphonia.

    • Cuff inflation anchors the larynx against the cervical spine, reducing laryngeal elevation, blunting subglottic pressure generation, and extinguishing sensory feedback.

Sagittal cross-section of tracheostomy tube placement with cuff in the trachea
  • Clinical Indications & Risks:

    • Indicated for acute respiratory failure, prolonged mechanical ventilation, traumatic brain injury, bilateral vocal fold paralysis, and terminal neuromuscular conditions.

    • Potential complications include tracheal stenosis, disuse vocal cord edema, secretion pooling, silent aspiration, and chronic ventilator dependency.

  • Speech-Language Pathology Care Protocol:

    • Evaluates tolerance of complete cuff deflation in conjunction with respiratory therapy and medical staff.

    • Assesses suitability for one-way speaking valves (e.g., Passy-Muir valve) to restore subglottic pressure, enhance olfaction, facilitate cough clearance, and re-establish oral communication.

    • Establishes low- or high-tech AAC modalities for non-vocal patients and implements swallow screening with oral-hygiene maintenance.